PriceTargets.com logo

Spruce Biosciences - SPRB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.60
  • Forecasted Upside: 247.03%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.19 As of 03/30/2023 01:00 AM ET
▲ +0.05 (2.34%)

This chart shows the closing price for SPRB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spruce Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPRB

Analyst Price Target is $7.60
▲ +247.03% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $7.60, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 247.03% upside from the last price of $2.19.

This chart shows the closing price for SPRB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Spruce Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2023HC WainwrightLower TargetBuy$20.00 ➝ $10.00Low
3/17/2023Credit Suisse GroupReiterated RatingOutperform$4.00Low
2/13/2023Royal Bank of CanadaLower TargetOutperform$9.00 ➝ $8.00Low
11/17/2022OppenheimerLower TargetOutperform$13.00 ➝ $8.00Low
11/16/2022JMP SecuritiesInitiated CoverageMarket Outperform$8.00Low
6/21/2022HC WainwrightReiterated RatingBuy$20.00Low
3/16/2022SVB LeerinkLower TargetMarket Perform$5.00 ➝ $3.00High
3/15/2022Royal Bank of CanadaLower TargetOutperform$13.00 ➝ $9.00Low
3/8/2022LADENBURG THALM/SH SHInitiated CoverageBuy$6.00High
1/25/2022HC WainwrightReiterated RatingBuy$20.00Low
1/6/2022HC WainwrightReiterated RatingBuy$20.00High
12/16/2021OppenheimerInitiated CoverageOutperform$15.00High
12/10/2021BenchmarkInitiated CoverageSpeculative Buy$7.00High
11/23/2021CowenDowngradeOutperform ➝ Market PerformMedium
11/16/2021Credit Suisse GroupLower TargetOutperform$26.00 ➝ $6.00High
11/16/2021HC WainwrightLower TargetBuy$30.00 ➝ $20.00High
11/16/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$35.00 ➝ $5.00High
8/26/2021HC WainwrightReiterated RatingBuy$30.00Low
7/19/2021HC WainwrightInitiated CoverageBuy$30.00High
5/18/2021SVB LeerinkReiterated RatingBuy$35.00High
3/23/2021Credit Suisse GroupLower TargetOutperform$28.00 ➝ $26.00High
11/3/2020SVB LeerinkInitiated CoverageOutperform$35.00High
11/3/2020Royal Bank of CanadaInitiated CoverageOutperform$28.00High
11/3/2020Credit Suisse GroupInitiated CoverageOutperform$28.00High
11/3/2020CowenInitiated CoverageOutperform$44.00High
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Spruce Biosciences logo
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Read More

Today's Range

Now: $2.19
Low: $2.14
High: $2.20

50 Day Range

MA: $2.53
Low: $2.14
High: $3.17

52 Week Range

Now: $2.19
Low: $0.95
High: $3.57

Volume

46,594 shs

Average Volume

1,583,804 shs

Market Capitalization

$87.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Spruce Biosciences?

The following Wall Street analysts have issued stock ratings on Spruce Biosciences in the last year: Credit Suisse Group AG, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., and Royal Bank of Canada.
View the latest analyst ratings for SPRB.

What is the current price target for Spruce Biosciences?

5 Wall Street analysts have set twelve-month price targets for Spruce Biosciences in the last year. Their average twelve-month price target is $7.60, suggesting a possible upside of 247.0%. HC Wainwright has the highest price target set, predicting SPRB will reach $10.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $4.00 for Spruce Biosciences in the next year.
View the latest price targets for SPRB.

What is the current consensus analyst rating for Spruce Biosciences?

Spruce Biosciences currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPRB will outperform the market and that investors should add to their positions of Spruce Biosciences.
View the latest ratings for SPRB.

What other companies compete with Spruce Biosciences?

Other companies that are similar to Spruce Biosciences include Verastem, Werewolf Therapeutics, Daré Bioscience, InterCure and Atossa Therapeutics. Learn More about companies similar to Spruce Biosciences.

How do I contact Spruce Biosciences' investor relations team?

The company's listed phone number is 415-655-4168 and its investor relations email address is [email protected] The official website for Spruce Biosciences is www.sprucebiosciences.com. Learn More about contacing Spruce Biosciences investor relations.